Home Cart Sign in  
Chemical Structure| 500-38-9 Chemical Structure| 500-38-9

Structure of Nordihydroguaiaretic acid
CAS No.: 500-38-9

Chemical Structure| 500-38-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Nordihydroguaiaretic Acid is a naturally occuring mTORC1 inhibitor.

Synonyms: NDGA; NSC 4291

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Wegner, Scott A ; Kim, Hahn ; Avalos, José L ;

Abstract: Lactate transport plays a crucial role in the metabolism, microenvironment, and survival of cancer cells. However, current drugs targeting either MCT1 or MCT4, which traditionally mediate lactate import or efflux respectively, show limited efficacy beyond in vitro models. This limitation partly arises from the existence of both isoforms in certain tumors, however existing high-affinity MCT1/4 inhibitors are years away from human testing. Therefore, we conducted an optogenetic drug screen in Saccharomyces cerevisiae on a subset of the FDA-approved drug library to identify existing scaffolds that could be repurposed as monocarboxylate transporter (MCT) inhibitors. Our findings show that several existing drug classes inhibit MCT1 activity, including non-steroidal estrogens, non-steroidal anti-inflammatory drugs (NSAIDs), and natural products (in total representing approximately 1% of the total library, 78 out of 6400), with a moderate affinity (IC50 1.8–21 μM). Given the well-tolerated nature of NSAIDs, and their known anticancer properties associated with COX inhibition, we chose to further investigate their MCT1 inhibition profile. The majority of NSAIDs in our screen cluster into a single large structural grouping. Moreover, this group is predominantly comprised of FDA-approved NSAIDs, with seven exhibiting moderate MCT1 inhibition. Since these molecules form a distinct structural cluster with known NSAID MCT4 inhibitors, such as diclofenac, ketoprofen, and indomethacin, we hypothesize that these newly identified inhibitors may also inhibit both transporters. Consequently, NSAIDs as a class, and piroxicam specifically (IC50 4.4 μM), demonstrate MCT1 inhibition at theoretically relevant human dosages, suggesting immediate potential for standalone MCT inhibition or combined anticancer therapy.

Purchased from AmBeed: ; ; ; ; ; ; ; ;

Alternative Products

Product Details of Nordihydroguaiaretic acid

CAS No. :500-38-9
Formula : C18H22O4
M.W : 302.36
SMILES Code : CC(CC1=CC=C(O)C(O)=C1)C(C)CC2=CC=C(O)C(O)=C2
Synonyms :
NDGA; NSC 4291
MDL No. :MFCD00002206
InChI Key :HCZKYJDFEPMADG-UHFFFAOYSA-N
Pubchem ID :4534

Safety of Nordihydroguaiaretic acid

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P301+P312+P330

Related Pathways of Nordihydroguaiaretic acid

PI3K-AKT

Isoform Comparison

Biological Activity

Target
  • p300/CBP

  • lipoxygenase

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02575794 High Grade Glioma (III or IV) Phase 1 Recruiting December 15, 2022 United States, Alabama ... More >> UAB Comprehensive Cancer Center Not yet recruiting Birmingham, Alabama, United States, 35294-3410 Contact: Thiru Pillay, RN    205-934-1842    thiru@uab.edu    Principal Investigator: Burt Nabors, MD          United States, California Jonsson Comprehensive Cancer Center at UCLA Not yet recruiting Los Angeles, California, United States, 90095 Contact: Timothy Cloughesy, MD    310-825-5321    TCloughesy@mednet.ucla.edu    Principal Investigator: Timothy Cloughesy, MD          United States, Maryland Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Recruiting Baltimore, Maryland, United States, 21231 Contact: Quinn qta@jhmi.edu, RN    410-955-8837    qta@jhmi.edu    Contact: Trisha Surakus    410-502-9864    tsuraku1@jhmi.edu    Sub-Investigator: Matthias Holdhoff, MD          Principal Investigator: Stuart Grossman, MD          United States, Massachusetts Dana Farber Cancer Institute Not yet recruiting Boston, Massachusetts, United States, 02215 Contact: Jennifer Barrs    617-632-6119    JenniferA_Barrs@DFCI.HARVARD.EDU    Principal Investigator: Patrick Wen, MD          United States, Michigan Josephine Ford Cancer Center at Henry Ford Hospital Recruiting Detroit, Michigan, United States, 48202 Contact: Amy Williamson, RN       awillia12@hfhs.org    Contact: Emily Krozek, MHSA       Ekrozek1@hfhs.org    Principal Investigator: Tobias Walbert, MD          United States, North Carolina Wake Forest University Comprehensive Cancer Center Not yet recruiting Winston-Salem, North Carolina, United States, 27157 Contact: Clinical Trials Office    336-713-6771       Principal Investigator: Glenn Lesser, MD          United States, Ohio Cleveland Clinic Taussig Cancer Center Not yet recruiting Cleveland, Ohio, United States, 44195 Contact: Cancer Center-Cares    216-444-7923       Sub-Investigator: David Peereboom, MD          United States, Pennsylvania Abrams Cancer Center of the University of Pennsylvania Not yet recruiting Philadelphia, Pennsylvania, United States, 19104 Contact: Clinical Trials Office-Abrams Cancer Center    800-474-9892       Principal Investigator: Arati Desai, MD          Hillman Cancer Center at University of Pittsburgh Cancer Institute Not yet recruiting Pittsburgh, Pennsylvania, United States, 15232 Contact: Clinical Trials Office - UPMC Cancer Centers    412-647-8073       Principal Investigator: Frank Lieberman, MD Less <<
NCT00664677 Leukemias Acu... More >>te Myeloid Leukemia (AML) Acute Lymphocytic Leukemia (ALL) Adult T Cell Leukemia (ATL) Chronic Myeloid Leukemia (CML-BP) Chronic Lymphocytic Leukemia (CLL) Myelodysplastic Syndrome (MDS) Chronic Myelomonocytic Leukemia (CMML) Less << Phase 1 Terminated(Funding constraints... More >>) Less << - United States, North Carolina ... More >> UNC, Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina, United States, 27599 Less <<
NCT00664586 Refractory Solid Tumors ... More >> Lymphoma Less << Phase 1 Terminated(Funding constraints... More >>) Less << - United States, Tennessee ... More >> The Sarah Cannon Cancer Center Nashville, Tennessee, United States, 37203 Less <<
NCT00259818 Cancer Phase 1 Completed - United States, Arizona ... More >> Premiere Oncology of Arizona Scottsdale, Arizona, United States United States, New York Albert Einstein College of Medicine Bronx, New York, United States United States, Tennessee Sarah Cannon Cancer Center Nashville, Tennessee, United States Less <<
NCT00057512 Head and Neck Neoplasms Phase 1 Completed - United States, South Carolina ... More >> MUSC Charleston, South Carolina, United States, 29475 Less <<
NCT00313534 Prostate Cancer Phase 1 Terminated(Ran out of drug) - United States, California ... More >> UCSF Comprehensive Cancer Center San Francisco, California, United States, 94115 Less <<
NCT00404248 Brain and Central Nervous Syst... More >>em Tumors Less << Phase 1 Phase 2 Completed - United States, Alabama ... More >> UAB Comprehensive Cancer Center Birmingham, Alabama, United States, 35294-3410 United States, Florida H. Lee Moffitt Cancer Center and Research Institute at University of South Florida Tampa, Florida, United States, 33612-9497 United States, Georgia Winship Cancer Institute of Emory University Atlanta, Georgia, United States, 30322 United States, Maryland Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, Maryland, United States, 21231 United States, Massachusetts Massachusetts General Hospital Boston, Massachusetts, United States, 02114 United States, Michigan Josephine Ford Cancer Center at Henry Ford Hospital Detroit, Michigan, United States, 48202 United States, North Carolina Wake Forest University Comprehensive Cancer Center Winston-Salem, North Carolina, United States, 27157-1096 United States, Ohio Cleveland Clinic Taussig Cancer Center Cleveland, Ohio, United States, 44195 United States, Pennsylvania Abramson Cancer Center of the University of Pennsylvania Philadelphia, Pennsylvania, United States, 19104-4283 Less <<
NCT00678015 Prostate Cancer Phase 2 Terminated(Per protocol - inte... More >>rim analysis showed no significant PSA declines among the first 12 patients after 3 cycles of treatment) Less << - United States, California ... More >> UCSF Helen Diller Family Comprehensive Cancer Center San Francisco, California, United States, 94115 Less <<
NCT00154089 Cervical Intraepithelial Neopl... More >>asia Less << Phase 1 Phase 2 Completed - United States, Maryland ... More >> University of Maryland, Dept. of Family Medicine Baltimore, Maryland, United States, 21201 Less <<
NCT00678015 - Terminated(Per protocol - inte... More >>rim analysis showed no significant PSA declines among the first 12 patients after 3 cycles of treatment) Less << - -
NCT00404248 - Completed - -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.31mL

0.66mL

0.33mL

16.54mL

3.31mL

1.65mL

33.07mL

6.61mL

3.31mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories